Chelators in the treatment of iron accumulation in parkinson's disease

International Journal of Cell Biology

Volumn , Issue , 2012, Pages

  Mounsey, Ross B ^a   Teismann, Peter ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CQ; DEFERIPRONE; DEFEROXAMINE MESYLATE; EPIGALLOCATECHIN GALLATE; IRON; IRON CHELATING AGENT; M30; MONOAMINE OXIDASE INHIBITOR; PHYTIC ACID; QUINOLINOL DERIVATIVE; UNCLASSIFIED DRUG; VK 28;

ANTIOXIDANT ACTIVITY; BETA THALASSEMIA; BLOOD BRAIN BARRIER; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HOMEOSTASIS; HUMAN; LIPID PEROXIDATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THALASSEMIA MAJOR;

EID: 84863639586     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2012/983245     Document Type: Review

References (109)

1. de Lau L. M., Breteler M. M., Epidemiology of Parkinson's disease The Lancet Neurology 2006 5 6 525 535 (Pubitemid 44262284)
2. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models Neuron 2003 39 6 889 909 (Pubitemid 37130207)
3. Rausch W., Hirata Y., Nagatsu T., Riederer P., Jellinger K., Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents Journal of Neurochemistry 1988 50 1 202 208 (Pubitemid 18023500)
4. Dexter D. T., Wells F. R., Agid F., Agid Y., Lees A. J., Jenner P., Marsden C. D., Increased nigral iron content in postmortem Parkinsonian brain Lancet 1987 2 8569 1219 1220 (Pubitemid 17156630)
5. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., Youdim M. B. H., Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain Journal of Neural Transmission, Supplementa 1988 74 3 199 205
6. Jenner P., Olanow C. W., Understanding cell death in Parkinson's disease Annals of Neurology 1998 44 3, supplement 1 S72 S84
7. Gerlach M., Double K. L., Youdim M. B. H., Riederer P., Potential sources of increased iron in the substantia nigra of Parkinsonian patients Journal of Neural Transmission, Supplementa 2006 70 2 133 142 (Pubitemid 44622190)
8. Kaur D., Andersen J., Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Research Reviews 2004 3 3 327 343 (Pubitemid 38844698)
9. Sengstock G. J., Olanow C. W., Menzies R. A., Dunn A. J., Arendash G. W., Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers Journal of Neuroscience Research 1993 35 1 67 82 (Pubitemid 23143633)
10. Wesemann W., Solbach M., Nafe R., Grote C., Sontag K. H., Riederer P., Jellinger K., Mennel H. D., Clement H. W., Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism Journal of Neural Transmission, Supplementa 1995 46 175 182 (Pubitemid 26046558)
11. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., Richardson R. J., Occupational exposures to metals as risk factors for Parkinson's disease Neurology 1997 48 3 650 658 (Pubitemid 27120101)
12. Berg D., Gerlach M., Youdim M. B. H., Double K. L., Zecca L., Riederer P., Becker G., Brain iron pathways and their relevance to Parkinson's disease Journal of Neurochemistry 2001 79 2 225 236 (Pubitemid 32988938)
13. Hentze M. W., Muckenthaler M. U., Andrews N. C., Balancing acts: molecular control of mammalian iron metabolism Cell 2004 117 3 285 297 (Pubitemid 38534536)
14. Thomson A. M., Rogers J. T., Leedman P. J., Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation International Journal of Biochemistry and Cell Biology 1999 31 10 1139 1152 (Pubitemid 29454550)
15. Pantopoulos K., Iron metabolism and the IRE/IRP regulatory system: an update Annals of the New York Academy of Sciences 2004 1012 1 13 (Pubitemid 38453511)
16. Zhu W., Li X., Xie W., Luo F., Kaur D., Andersen J. K., Jankovic J., Le W., Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration Neurobiology of Disease 2010 37 2 307 313
17. Faucheux B. A., Martin M., Beaumont C., Hauw J., Agid Y., Hirsch E. C., Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease Journal of Neurochemistry 2003 86 5 1142 1148 (Pubitemid 37022190)
18. Gtz M. E., Double K., Gerlach M., Youdim M. B. H., Riederer P., The relevance of iron in the pathogenesis of Parkinson's disease Annals of the New York Academy of Sciences 2004 1012 193 208 (Pubitemid 38455479)
19. Zecca L., Youdim M. B. H., Riederer P., Connor J. R., Crichton R. R., Iron, brain ageing and neurodegenerative disorders Nature Reviews Neuroscience 2004 5 11 863 873 (Pubitemid 39482155)
20. Sian-Hlsmann J., Mandel S., Youdim M. B. H., Riederer P., The relevance of iron in the pathogenesis of Parkinson's disease Journal of Neurochemistry 2011 118 6 939 957
21. Youdim M. B. H., Ben-Shachar D., Riederer P., The possible role of iron in the etiopathology of Parkinson's disease Movement Disorders 1993 8 1 1 12 (Pubitemid 23039223)
22. Youdim M. B. H., Stephenson G., Shachar D. B., Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28 Annals of the New York Academy of Sciences 2004 1012 306 325 (Pubitemid 38453534)
23. Gutteridge J. M. C., Hydroxyl radicals, iron, oxidative stress, and neurodegeneration Annals of the New York Academy of Sciences 1994 738 201 213
24. Perry T. L., Godin D. V., Hansen S., Parkinson's disease: a disorder due to nigral glutathione deficiency? Neuroscience Letters 1982 33 3 305 310 (Pubitemid 13119539)
25. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C. D., Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Annals of Neurology 1994 36 3 348 355 (Pubitemid 24280055)
26. Aisen P., Wessling-Resnick M., Leibold E. A., Iron metabolism Current Opinion in Chemical Biology 1999 3 2 200 206 (Pubitemid 29145787)
27. Harrison P. M., Arosio P., The ferritins: molecular properties, iron storage function and cellular regulation Biochimica et Biophysica Acta 1996 1275 3 161 203 (Pubitemid 26248989)
28. Arosio P., Ferritin L. S., Iron homeostasis, and oxidative damage Free Radical Biology and Medicine 2002 33 4 457 463
29. Jellinger K. A., The role of iron in neurodegeneration. prospects for pharmacotherapy of Parkinson's disease Drugs and Aging 1999 14 2 115 140 (Pubitemid 29086113)
30. Rucker P., Torti F. M., Torti S. V., Role of H and L subunits in mouse ferritin Journal of Biological Chemistry 1996 271 52 33352 33357 (Pubitemid 27010145)
31. Friedman A., Arosio P., Finazzi D., Koziorowski D., Galazka-Friedman J., Ferritin as an important player in neurodegeneration Parkinsonism and Related Disorders 2011 17 6 423 430
32. Curtis A. R. J., Fey C., Morris C. M., Bindoff L. A., Ince P. G., Chinnery P. F., Coulthard A., Jackson M. J., Jackson A. P., McHale D. P., Hay D., Barker W. A., Markham A. F., Bates D., Curtis A., Burn J., Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease Nature Genetics 2001 28 4 350 354 (Pubitemid 32702424)
33. Morris C. M., Candy J. M., Omar S., Bloxham C. A., Edwardson J. A., Transferrin receptors in the Parkinsonian midbrain Neuropathology and Applied Neurobiology 1994 20 5 468 472 (Pubitemid 24326469)
34. Faucheux B. A., Hauw J., Agid Y., Hirsch E. C., The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease Brain Research 1997 749 1 170 174 (Pubitemid 27096473)
35. Connor J. R., Snyder B. S., Arosio P., Loeffler D. A., Lewitt P., A quantitative analysis of isoferritins in select regions of aged, Parkinsonian, and Alzheimer's diseased brains Journal of Neurochemistry 1995 65 2 717 724
36. Zecca L., Gallorini M., Schnemann V., Trautwein A. X., Gerlach M., Riederer P., Vezzoni P., Tampellini D., Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes Journal of Neurochemistry 2001 76 6 1766 1773 (Pubitemid 32221116)
37. Hallgren B., Sourander P., The effect of age on the non-haemin iron in the human brain Journal of Neurochemistry 1958 3 1 41 51
38. Monteiro H. P., Winterbourn C. C., 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation Biochemical Pharmacology 1989 38 23 4177 4182 (Pubitemid 20009013)
39. Double K. L., Maywald M., Schmittel M., Riederer P., Gerlach M., In vitro studies of ferritin iron release and neurotoxicity Journal of Neurochemistry 1998 70 6 2492 2499 (Pubitemid 28252375)
40. Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y., Hirsch E. C., Nuclear translocation of NF- b is increased in dopaminergic neurons of patients with Parkinson disease Proceedings of the National Academy of Sciences of the United States of America 1997 94 14 7531 7536 (Pubitemid 27345350)
41. Przedborski S., Vila M., The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease Annals of the New York Academy of Sciences 2003 991 189 198 (Pubitemid 36793814)
42. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., Greenamyre J. T., Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nature Neuroscience 2000 3 12 1301 1306
43. Bové J., Prou D., Perier C., Przedborski S., Toxin-induced models of Parkinson's disease NeuroRx 2005 2 3 484 494 (Pubitemid 41444882)
44. Teismann P., Mounsey R. B., Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection Parkinson's Disease 2011 2011 18
45. Lan J., Jiang D. H., Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease Journal of Neural Transmission, Supplementa 1997 104 6-7 649 660 (Pubitemid 27474679)
46. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L. M., Nuez M. T., Garrick M. D., Raisman-Vozari R., Hirsch E. C., Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease Proceedings of the National Academy of Sciences of the United States of America 2008 105 47 18578 18583
47. Olanow C. W., Oxidation reactions in Parkinson's disease Neurology 1990 40 10, supplement 3 32 39
48. Shamoto-Nagai M., Maruyama W., Yi H., Akao Y., Tribl F., Gerlach M., Osawa T., Riederer P., Naoi M., Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome Journal of Neural Transmission, Supplementa 2006 113 5 633 644 (Pubitemid 43673603)
49. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., Goedert M., -synuclein in Lewy bodies Nature 1997 388 6645 839 840
50. Xu J., Kao S. Y., Lee F. J. S., Song W., Jin L. W., Yankner B. A., Dopamine-dependent neurotoxicity of -synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nature Medicine 2002 8 6 600 606 (Pubitemid 34633438)
51. Mandel S., Maor G., Youdim M. B. H., Iron and -synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate Journal of Molecular Neuroscience 2004 24 3 401 416 (Pubitemid 41389377)
52. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farer M., Wolozin B., The A53T -synuclein mutation increases iron-dependent aggregation and toxicity Journal of Neuroscience 2000 20 16 6048 6054 (Pubitemid 30658398)
53. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C. D., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease Journal of Neurochemistry 1989 52 2 381 389 (Pubitemid 19037600)
54. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R., Mizuno Y., Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proceedings of the National Academy of Sciences of the United States of America 1996 93 7 2696 2701 (Pubitemid 26114311)
55. Liu W., Kato M., Akhand A. A., Hayakawa A., Suzuki H., Miyata T., Kurokawa K., Hotta Y., Ishikawa N., Nakashima I., 4-Hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death Journal of Cell Science 2000 113 4 635 641 (Pubitemid 30133041)
56. Picklo M. J., Amarnath V., McIntyre J. O., Graham D. G., Montine T. J., 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites Journal of Neurochemistry 1999 72 4 1617 1624 (Pubitemid 29140836)
57. Castellani R. J., Siedlak S. L., Perry G., Smith M. A., Sequestration of iron by Lewy bodies in Parkinson's disease Acta Neuropathologica 2000 100 2 111 114 (Pubitemid 30456131)
58. Uversky V. N., Li J., Fink A. L., Metal-triggered structural transformations, aggregation, and fibrillation of human -synuclein: a possible molecular link between parkinson's disease and heavy metal exposure Journal of Biological Chemistry 2001 276 47 44284 44296
59. Hashimoto M., Takeda A., Hsu L. J., Takenouchi T., Masliah E., Role of cytochrome c as a stimulator of -synuclein aggregation in Lewy body disease Journal of Biological Chemistry 1999 274 41 28849 28852
60. Leggio L., Addolorato G., Abenavoli L., Gasbarrini G., Wilson's disease: clinical, genetic and pharmacological findings International Journal of Immunopathology and Pharmacology 2005 18 1 7 14 (Pubitemid 40343454)
61. Youdim M. B. H., Grnblatt E., Mandel S., The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice Journal of Neural Transmission, Supplementa 2007 114 2 205 209 (Pubitemid 46147157)
62. Liu Z. D., Hider R. C., Design of clinically useful iron(III)-selective chelators Medicinal Research Reviews 2002 22 1 26 64 (Pubitemid 34023572)
63. Gaeta A., Hider R. C., The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy British Journal of Pharmacology 2005 146 8 1041 1059 (Pubitemid 41786957)
64. Dexter D. T., Statton S. A., Whitmore C., Freinbichler W., Weinberger P., Tipton K. F., Della Corte L., Ward R. J., Crichton R. R., Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration Journal of Neural Transmission, Supplementa 2011 118 2 223 231
65. Forni G. L., Balocco M., Cremonesi L., Abbruzzese G., Parodi R. C., Marchese R., Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation Movement Disorders 2008 23 6 904 907
66. Zorzi G., Zibordi F., Chiapparini L., Bertini E., Russo L., Piga A., Longo F., Garavaglia B., Aquino D., Savoiardo M., Solari A., Nardocci N., Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial Movement Disorders 2011 26 9 1755 1759
67. Youdim M. B. H., Grnblatt E., Mandel S., The pivotal role of iron in NF- B activation and nigrostriatal dopaminergic neurodegeneration. prospects for neuroprotection in Parkinson's disease with iron chelators Annals of the New York Academy of Sciences 1999 890 7 25 (Pubitemid 30040361)
68. Ben Shachar D., Kahana N., Kampel V., Warshawsky A., Youdim M. B. H., Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats Neuropharmacology 2004 46 2 254 263 (Pubitemid 37532833)
69. Gal S., Zheng H., Fridkin M., Youdim M. B. H., Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. in vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion Journal of Neurochemistry 2005 95 1 79 88 (Pubitemid 41384427)
70. Zheng H., Gal S., Weiner L. M., Bar-Am O., Warshawsky A., Fridkin M., Youdim M. B. H., Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition Journal of Neurochemistry 2005 95 1 68 78 (Pubitemid 41384426)
71. Zhu W., Xie W., Pan T., Prevention and restoration of lactacystein-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable brain chelators The FASEB Journal 21 14 3835 3844
72. Yassin M. S., Ekblom J., Xilinas M., Gottfries C. G., Oreland L., Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol Journal of the Neurological Sciences 2000 173 1 40 44 (Pubitemid 30081774)
73. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J. Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M. F., DiMonte D., Volitaskis I., Ellerby L., Cherny R. A., Bush A. I., Andersen J. K., Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease Neuron 2003 37 6 899 909 (Pubitemid 36398297)
74. Reznichenko L., Kalfon L., Amit T., Youdim M. B. H., Mandel S. A., Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism Neurodegenerative Diseases 2010 7 4 219 231
75. Leaver K. R., Allbutt H. N., Creber N. J., Kassiou M., Henderson J. M., Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection Brain Research Bulletin 2009 80 6 397 402
76. Xu Q., Kanthasamy A. G., Reddy M. B., Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease Toxicology 2008 245 1-2 101 108
77. Xu Q., Kanthasamy A. G., Reddy M. B., Phytic acid protects against 6-hydroxydopamine-induced dopaminergic neuron apoptosis in normal and iron excess conditions in a cell culture model Parkinson's Disease 2011 2011 6
78. Liu Z. D., Hider R. C., Design of iron chelators with therapeutic application Coordination Chemistry Reviews 2002 232 1-2 151 171
79. Olivieri N. F., Brittenham G. M., Iron-chelating therapy and the treatment of thalassemia Blood 1997 89 3 739 761 (Pubitemid 27121266)
80. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., Gitlin J. D., Use of desferrioxamine in the treatment of aceruloplasminemia Annals of Neurology 1997 41 3 404 407 (Pubitemid 27114054)
81. Polson R. J., Jawed A., Bomford A., Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects British Medical Journal 1985 291 6493 448 (Pubitemid 15012891)
82. Sangchot P., Sharma S., Chetsawang B., Porter J., Govitrapong P., Ebadi M., Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and -synuclein translocation in SK-N-SH cells in culture Developmental Neuroscience 2002 24 2-3 143 153 (Pubitemid 36151444)
83. Santiago M., Matarredona E. R., Granero L., Cano J., Machado A., Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals Journal of Neurochemistry 1997 68 2 732 738 (Pubitemid 27044738)
84. Ben-Shachar D., Eshel G., Finberg J. P. M., Youdim M. B. H., The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons Journal of Neurochemistry 1991 56 4 1441 1444 (Pubitemid 21902069)
85. Jiang H., Luan Z., Wang J., Xie J., Neuroprotective effects of iron chelator desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload Neurochemistry International 2006 49 6 605 609 (Pubitemid 44528090)
86. Lan J., Jiang D. H., Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice Journal of Neural Transmission, Supplementa 1997 104 4-5 469 481 (Pubitemid 27379903)
87. Zhang X., Xie W., Qu S., Pan T., Wang X., Le W., Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration Biochemical and Biophysical Research Communications 2005 333 2 544 549 (Pubitemid 40848325)
88. Forni G. L., Ferrochelating treatment in patients affected by neurodegeneration with brain iron accumulation. January 2012, http://clinicaltrials.gov/ct2/show/NCT00907283?term= iron+chelator+neurodegenerationrank=2
89. Devos D., Efficacy and safety of the iron chelator deferiprone in Parkinson's disease (FAIR-PARK-I). March 2012, http://clinicaltrials.gov/ct2/ show/NCT00943748?term=iron+chelator+neurodegenerationrank=1
90. Dexter D., A pilot clinical trial with the iron chelator deferiprone in Parkinson's Disease (DeferipronPD). March 2012, http://clinicaltrials.gov/ct2/ show/NCT01539837?term=iron+chelatorrank=2
91. Grnblatt E., Mandel S., Gassen M., Youdim M. B. H., Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity Journal of Neural Transmission, Supplementa 1999 55 57 70 (Pubitemid 29195797)
92. Gassen M., Glinka Y., Pinchasi B., Youdim M. B. H., Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction European Journal of Pharmacology 1996 308 2 219 225 (Pubitemid 26237050)
93. Grnblatt E., Mandel S., Maor G., Youdim M. B. H., Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss Journal of Neurochemistry 2001 77 1 146 156 (Pubitemid 32245088)
94. Youdim M. B. H., Gassen M., Gross A., Mandel S., Grunblatt E., Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine Journal of Neural Transmission, Supplementa 2000 58 83 96
95. Pierre J. L., Baret P., Serratrice G., Hydroxyquinolines as iron chelators Current Medicinal Chemistry 2003 10 12 1077 1084 (Pubitemid 36588329)
96. Zheng H., Weiner L. M., Bar-Am O., Epsztejn S., Cabantchik Z. I., Warshawsky A., Youdim M. B. H., Fridkin M., Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases Bioorganic and Medicinal Chemistry 2005 13 3 773 783 (Pubitemid 40093620)
97. Youdim M. B. H., Rasagiline: an anti-Parkinson drug with neuroprotective activity Expert Review of Neurotherapeutics 2003 3 6 737 749 (Pubitemid 37462173)
98. Kidani Y., Naga S., Koike H., Mass spectrometry of 5-chloro-7-iodo-8- quinol metal chelates Japan Analyst 1974 23 1375 1378
99. Cherny R. A., Atwood C. S., Xilinas M. E., Gray D. N., Jones W. D., McLean C. A., Barnham K. J., Volitakis I., Fraser F. W., Kim Y. S., Huang X., Goldstein L. E., Moir R. D., Lim J. T., Beyreuther K., Zheng H., Tanzi R. E., Masters C. L., Bush A. I., Treatment with a copper-zinc chelator markedly and rapidly inhibits -amyloid accumulation in Alzheimer's disease transgenic mice Neuron 2001 30 3 665 676 (Pubitemid 32607332)
100. Nijveldt R. J., Van Nood E., Van Hoorn D. E. C., Boelens P. G., Van Norren K., Van Leeuwen P. A. M., Flavonoids: a review of probable mechanisms of action and potential applications American Journal of Clinical Nutrition 2001 74 4 418 425 (Pubitemid 32880250)
101. Grinberg L. N., Newmark H., Kitrossky N., Rahamim E., Chevion M., Rachmilewitz E. A., Protective effects of tea polyphenols against oxidative damage to red blood cells Biochemical Pharmacology 1997 54 9 973 978 (Pubitemid 27475235)
102. Chan D. K. Y., Woo J., Ho S. C., Pang C. P., Law L. K., Ng P. W., Hung W. T., Kwok T., Hui E., Orr K., Leung M. F., Kay R., Genetic and environmental risk factors for Parkinson's disease in a Chinese population Journal of Neurology Neurosurgery and Psychiatry 1998 65 5 781 784 (Pubitemid 28486664)
103. Levites Y., Weinreb O., Maor G., Youdim M. B. H., Mandel S., Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration Journal of Neurochemistry 2001 78 5 1073 1082 (Pubitemid 32823156)
104. Mandel S. A., Avramovich-Tirosh Y., Reznichenko L., Zheng H., Weinreb O., Amit T., Youdim M. B. H., Multifunctional activities of green tea catechins in neuroprotection: modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway NeuroSignals 2005 14 1-2 46 60 (Pubitemid 40868983)
105. Lu H., Meng X., Yang C. S., Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate Drug Metabolism and Disposition 2003 31 5 572 579 (Pubitemid 36444166)
106. Shamsuddin A. M., Vucenik I., Cole K. E., IP6: a novel anti-cancer agent Life Sciences 1997 61 4 343 354
107. Obata T., Phytic acid suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum Brain Research 2003 978 1-2 241 244 (Pubitemid 36776645)
108. Li K., Besse E. K., Ha D., Kovtunovych G., Rouault T. A., Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia Human Molecular Genetics 2008 17 15 2265 2273
109. Boddaert N., Sang K. H. L. Q., Rtig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J. C., Munnich A., Cabantchik Z. I., Selective iron chelation in Friedreich ataxia: biologic and clinical implications Blood 2007 110 1 401 408 (Pubitemid 47026862)